BioBlast Pharma (ORPN) Tops Q2 EPS by 5c
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
BioBlast Pharma (Nasdaq: ORPN) reported Q2 EPS of ($0.22), $0.05 better than the analyst estimate of ($0.27).
Cash and cash equivalents (including short-term bank deposits) totaled $15.7 million at June 30, 2016, compared with $19.3 million at December 31, 2015.
For earnings history and earnings-related data on BioBlast Pharma (ORPN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vera Bradley (VRA) Tops Q3 EPS by 1c; Offers Light Q4 Outlook; Enters New Licensing Agreements
- Brown-Forman (BF-A) Reports Inline Q2 EPS
- Korn/Ferry International (KFY) Misses Q2 EPS by 5c
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!